Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Hormone-sensitive Prostate Cancer × apalutamide × 90 days × Clear all

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 33 Stage II Prostate Adenocarcinoma 1 Salivary Gland Neoplasms 1 Non-Muscle Invasive Bladder Urothelial Carcinoma 1 Neoplasm Metastasis 1 Metastatic Hormone-sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castrate-sensitive Prostate Cancer 1 Castration Levels of Testosterone 1 Adenocarcinoma 1

Interventions

enzalutamide 2 apalutamide 1 abiraterone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05901649 2026-03-13

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡